Company: CDLX
Filing Date: 2025-04-03
Form Type: DEF 14A
Source: 0001666071-25-000046
Chunk: 29

Company: Cardlytics, Inc.
Filing Date: 2025-04-03
Form: DEF 14A
Chunk 29
---
|:----|:----|-----------:|:--|:----|:----|-----------:|:--|
| Total number of shares subject to stock options granted                           |     |                         |          — |   |     |     |          — |   |     |     |          — |   |
| Total number of shares subject to time-based restricted stock units granted       |     |                         |  4,948,914 |   |     |     |  3,559,268 |   |     |     |  5,786,293 |   |
| Total number of shares subject to performance-based restricted stock units earned |     |                         |          — |   |     |     |          — |   |     |     |    395,440 |   |
| Weighted-average number of common shares outstanding                              |     |                         | 48,360,266 |   |     |     | 36,488,266 |   |     |     | 33,418,844 |   |
| Gross Burn Rate(1)                                                                |     |                         |         10 | % |     |     |         10 | % |     |     |         18 | % |

(1) Calculated as: shares subject to equity awards granted and, in the case of performance-based restricted stock units, earned, divided by weighted-average common shares outstanding for each fiscal year.

#### Key Plan Features
The 2025 Plan includes provisions that are designed to protect our stockholders’ interests and to reflect corporate governance best practices including:

• Stockholder approval is required for additional shares. The 2025 Plan does not contain an annual “evergreen” provision. The 2025 Plan authorizes a fixed number of shares, so that stockholder approval is required to issue any additional shares, allowing our stockholders to have direct input on our equity compensation programs.

• Repricing is not allowed without stockholder approval . The 2025 Plan prohibits the repricing of outstanding stock options and stock appreciation rights and the cancellation of any outstanding stock options or stock appreciation rights that have an exercise or strike price greater than the then-current fair market value of our shares in exchange for cash or other stock awards under the 2025 Plan without prior stockholder approval.

• No discounted stock options or stock appreciation rights . All stock options and stock appreciation rights granted under the 2025 Plan must have an exercise price equal to or greater than the fair market value of our common stock on the